These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 12805482)
1. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482 [TBL] [Abstract][Full Text] [Related]
2. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Ban N; Takahashi Y; Takayama T; Kura T; Katahira T; Sakamaki S; Niitsu Y Cancer Res; 1996 Aug; 56(15):3577-82. PubMed ID: 8758929 [TBL] [Abstract][Full Text] [Related]
3. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme. Wang W; Liu G; Zheng J Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556 [TBL] [Abstract][Full Text] [Related]
4. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968 [TBL] [Abstract][Full Text] [Related]
5. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092 [TBL] [Abstract][Full Text] [Related]
6. Potent isozyme-selective inhibition of human glutathione S-transferase A1-1 by a novel glutathione S-conjugate. Cacciatore I; Caccuri AM; Cocco A; De Maria F; Di Stefano A; Luisi G; Pinnen F; Ricci G; Sozio P; Turella P Amino Acids; 2005 Nov; 29(3):255-61. PubMed ID: 16082503 [TBL] [Abstract][Full Text] [Related]
7. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer. Wang Z; Cai L; Wang H Gynecol Oncol; 2005 Mar; 96(3):643-50. PubMed ID: 15721406 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma. Seitz G; Bonin M; Fuchs J; Poths S; Ruck P; Warmann SW; Armeanu-Ebinger S Int J Oncol; 2010 Feb; 36(2):491-500. PubMed ID: 20043085 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of ethacrynic acid analogues on glutathione-s-transferase P1-1 activity inhibition. Zhao G; Yu T; Wang R; Wang X; Jing Y Bioorg Med Chem; 2005 Jun; 13(12):4056-62. PubMed ID: 15911318 [TBL] [Abstract][Full Text] [Related]
10. Proapoptotic activity of new glutathione S-transferase inhibitors. Turella P; Cerella C; Filomeni G; Bullo A; De Maria F; Ghibelli L; Ciriolo MR; Cianfriglia M; Mattei M; Federici G; Ricci G; Caccuri AM Cancer Res; 2005 May; 65(9):3751-61. PubMed ID: 15867371 [TBL] [Abstract][Full Text] [Related]
11. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490 [TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Zhang T; Guan M; Jin HY; Lu Y Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151 [TBL] [Abstract][Full Text] [Related]
13. [Glutathione S transferases-pi]. Takahashi Y; Niitsu Y Gan To Kagaku Ryoho; 1994 Jun; 21(7):945-51. PubMed ID: 8002632 [TBL] [Abstract][Full Text] [Related]
14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
15. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Tew KD; Monks A; Barone L; Rosser D; Akerman G; Montali JA; Wheatley JB; Schmidt DE Mol Pharmacol; 1996 Jul; 50(1):149-59. PubMed ID: 8700107 [TBL] [Abstract][Full Text] [Related]
17. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711 [TBL] [Abstract][Full Text] [Related]
18. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV). Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627 [TBL] [Abstract][Full Text] [Related]
19. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185 [TBL] [Abstract][Full Text] [Related]
20. Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line. Yang JX; Luo Y; Qiu HM; Tang WX Saudi Med J; 2009 Jan; 30(1):35-40. PubMed ID: 19139770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]